Diagnostic value of using exosome-derived cysteine-rich protein 61 as biomarkers for acute coronary syndrome

WEI LI, YI LI, WEI ZHI, CHEN LIU, WEIZE FAN, QING MIAO and XINSHUN GU

Department of Cardiovascular Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China

Received April 7, 2020; Accepted August 5, 2021

DOI: 10.3892/etm.2021.10872

Abstract. Acute coronary syndrome (ACS) is the main manifestation of cardiovascular disease and the primary cause of adult hospitalization in China. There is an urgent demand for novel biomarkers for the diagnosis of ACS. Although plasma cysteine-rich protein 61 (Cyr61) has been previously reported to be accurate for ACS diagnosis, the accuracy of exosomal Cyr61 in ACS diagnosis remains unknown. In the present study, the aim was to assess the potential of applying exosomal Cyr61 in ACS diagnosis and to explore the role of Cyr61 in vascular remodeling in vitro. The abundance of Cyr61 in plasma-derived exosomes from patients with unstable angina pectoris (UAP), acute myocardial infarction (AMI) patients in addition to those isolated from healthy individuals were detected using an ELISA kit. The association between exosomal Cyr61 levels and clinical characteristics of ACS patients was analyzed through $\chi^2$ test, Fisher's exact test and Student's t-test. Receiver operating characteristic (ROC) curve analysis was used to determine the accuracy of using exosomal Cyr61 as a biomarker of ACS diagnosis. Furthermore, independent predictors of the existence of ACS were investigated through a multivariate analysis. Subsequently, the role of Cyr61 on vascular remodeling was evaluated in vascular smooth muscle cells (VSMCs) upon oxidized low-density lipoprotein (ox-LDL) treatment by performing Cyr61 knockdown, Cell Counting Kit-8, flow cytometry and Transwell assays. Exosomal Cyr61 expression was found to be significantly elevated in patients with ACS compared with that in healthy individuals. In addition, exosomal Cyr61 levels were associated with sex, family history of ACS and glucose levels. ROC curve analyzes revealed that exosomal Cyr61 expression could be used to differentiate patients with UAP, AMI and ACS from healthy individuals. Furthermore, exosomal Cyr61 levels were independently correlated with the existence of ACS. In vitro, Cyr61 expression was demonstrated to be significantly increased in VSMCs after ox-LDL exposure in a concentration- and time-dependent manner. Functionally, the elevated cell viability and migration of VSMCs induced by ox-LDL were partially but significantly inhibited by Cyr61 knockdown. By contrast, knocking down Cyr61 expression significantly elevated the apoptosis rate of VSMCs compared with that in the ox-LDL-treated group. In conclusion, data from the present study suggest that Cyr61 serve a regulatory role in vascular remodeling in vitro, where exosomal Cyr61 levels may represent a promising biomarker for ACS diagnosis.

Introduction

Acute coronary syndrome (ACS) is the most common type of severe heart disease, which is mainly caused by damage to major blood vessels, such as coronary vessels (1-3). ACS defines a group of cardiovascular diseases, including unstable angina pectoris (UAP) and acute myocardial infarction (AMI) (3). Although current treatment strategies of ACS, including percutaneous coronary angioplasty and the tirofiban drug, have been developed for treating ACS, this disease was responsible for >40% of all mortality of coronary heart disease in China in 2017 (4,5). Currently available diagnostic methods, such as coronary angiography or echocardiography, fail to simultaneously achieve the goals of convenience of application or high sensitivity, significantly increasing the rate of misdiagnosis (6,7). It has been previously reported that circulating brain natriuretic peptide, high-sensitivity C-reactive protein (hs-CRP) and myocardial enzymes can all predict the incidence of cardiovascular events (8,9). However, an increase in the levels of these biomarkers has also been found in other inflammatory diseases, including periodontal disease and rheumatoid arthritis (10,11). Therefore, identification of novel biomarkers with high sensitivity and convenience for ACS diagnosis would improve the outcome of this disease following treatment at earlier stages.

Exosomes are small microvesicles with sizes of 30-150 nm that have the capacity to carry proteins, microRNAs (miR or miRNA) and long noncoding RNAs (lncRNAs) (12,13). Accumulating evidence has demonstrated that exosomes can serve as messengers in mediating inflammation, vascular damage and apoptosis (13,14). In particular, exosomes...
have also been previously found to be involved in the pathophysiological process of ACS (15,16). Yao et al (17) revealed that platelet-derived exosomal miR-25-3p suppressed the inflammation of coronary artery vascular endothelial cells by inhibiting the NF-κB pathway. Li et al (18) reported that platelet-derived exosomes activated by thrombin downregulated the endothelial cell expression of intercellular cell adhesion molecule-1 through miR-223 during the thrombosis-inflammatory response. In addition, previous studies have demonstrated that both exosomal surface molecules and its contents can be potentially applied as biomarkers for ACS diagnosis (3,19,20). Li et al (20) reported that using serum-derived exosomal miR-146a levels conferred high accuracy as a novel diagnostic biomarker for ACS. In addition, serum exosomal miR-122-5p was found to be an independent biomarker for ACS (19). Therefore, the aforementioned observations suggest that exosomes can be used as potentially non-invasive biomarkers for ACS.

Cysteine-rich protein 61 (Cyr61) has emerged as a potential regulator of neovascularization, inflammation, thrombosis and hemostasis, in addition to tissue remodeling (21,22). Klingenberg et al (23) reported that serum Cyr61 levels were significantly elevated in patients with ST-elevation myocardial infarction compared with those in patients with non-ST-elevation myocardial infarction/unstable angina or stable ACS, irrespective of whether coronary thrombi were present. Furthermore, Liu et al (24) found that serum Cyr61 levels showed markedly accuracy in predicting the presence of ACS by using receiver operating characteristic (ROC) curve analysis. However, the potential role of exosomal Cyr61 in discriminating patients with ACS from other similar conditions remains poorly understood. Therefore, the present study was designed to assess the potential of exosomal Cyr61 as a biomarker for ACS diagnosis and to investigate the role of Cyr61 in vascular remodeling in vitro.

Materials and methods

Patient samples. In total, 210 patients with ACS (male, 146; female, 54; age, 66.28±10.47) who received coronary stent implantation or medical treatment at the Second Hospital of Hebei Medical University (Shijiazhuang, China) between January 2016 and June 2020 were recruited for the present study. Recruited patients exhibited symptoms compatible with angina pectoris (dyspnea and chest pain) and fulfilled ≥ one of the following criteria (25): i) Rise in serial troponin levels (the normal range of troponin being 0-0.04 ng/ml). The troponin level was detected at the time of admission. It was checked every 4 h in the first 24 h, every 8 h in the second 24 h and once in the third 24 h; ii) persistent ST-segment depression or elevation, dynamic electrocardiogram (ECG) changes or T-inversion, new left bundle branch block; and iii) diameter of coronary artery luminal stenosis ≥50% as detected by coronary angiography. The exclusion criteria were the following: i) Presence of inflammation, infection, autoimmune diseases, progressive hepatic and renal insufficiency, and tumor history; ii) history of ACS; and iii) pregnancy. Based on their clinical diagnoses, 160 patients with ACS were diagnosed with UAP and 50 patients with AMI. UAP is usually triggered by physical exercise, emotional excitement or a cold environment. The attack time is short and frequent. Nitroglycerin treatment can significantly alleviate the symptoms. For AMI, there is no obvious trigger. The attack time is long and up to several hours. There is no remission after nitroglycerin treatment. Patients often have fever, increased leukocytes and rapid erythrocyte sedimentation rate. The patients display a necrotic Q wave in ECG (26).

In addition, 50 healthy individuals with a mean age of 64.56±9.61 years (male, 22; female, 28) who underwent physical examination at the Second Hospital of Hebei Medical University (Shijiazhuang, China) were recruited in the present study as the control group between January 2016 and June 2020. All healthy subjects had normal coronary arteries and history with normal ECG characteristics and/or ECG treadmill test results. Participants with severe concomitant diseases, including cardiomyopathy, congenital heart disease, cerebrovascular or peripheral vascular diseases, trauma or surgery within the last 3 months, chronic or acute infection, malignant tumors, immune diseases, hepatic or renal failure or a history of recent cardiopulmonary resuscitation were excluded from this study.

The present study was approved by the Institutional Ethics Committee of the Second Hospital of Hebei Medical University. Written informed consent was obtained from every participant in the present study. A total of 5 ml peripheral blood samples were obtained from patients with ACS at the time of diagnosis and healthy individuals. Cell-free plasma was isolated within 6 h after collection by centrifugation at 4°C (1,000 x g for 10 min), before being stored at -80°C until further experimentation.

Exosome isolation and identification. Exosomes were collected from the plasma by sequential ultracentrifugation. Plasma was centrifuged at 3,000 x g for 20 min at 4°C, followed by centrifugation at 12,000 x g for 20 min at 4°C. Subsequently, exosomes were collected by ultracentrifugation (100,000 x g for 70 min at 4°C) in the pellet. After suspension in 20 ml PBS, the exosomes were collected again by ultracentrifugation (100,000 x g for 70 min at 4°C) in the pellet. The morphological characteristics of the exosomes were verified by transmission electron microscopy. Nanoparticle tracking analysis (NTA) using a Malvern Zetasizer Nano ZS90 (Malvern Panalytical) was performed to measure the concentration and size of exosomes.

Transmission electron microscopy. Freshly prepared exosomes (100 μg) were diluted in PBS (20 ml) and fixed with 3.5% glutaraldehyde for 5 min at 4°C. Subsequently, exosome preparation was allowed to adsorb in a mesh copper grid. The resulting grids were rinsed two times with wash buffer and contrasted by 2% uranyl-oxalate solution (pH 7.0) for 5 min at 25°C. The visualization of exosomes morphology was performed using a H-9500 transmission electron microscope (Hitachi, Ltd.) at 300 kV, images were acquired using a F114 slow-scan CCD camera (Tietz Video and Image Processing Systems GmbH) and analyzed using EM-Menu v3.0 basic (Tietz Video and Image Processing Systems GmbH).

Western blotting. Exosomes and vascular smooth muscle cells (VSMCs) were lysed using RIPA buffer containing...
protease inhibitors (Beyotime Institute of Biotechnology). Each sample was quantified by BCA protein quantitative kit (Beijing Solarbio Science & Technology Co., Ltd.). Subsequently, 50 μg of protein per lane were separated by 10% SDS-PAGE and transferred onto 0.22-μm PVDF membranes. The membranes were then blocked with 5% non-fat milk for 60 min at 25°C. The membranes were subsequently incubated with primary antibodies against CD9 (dilution 1:1,000; cat. no. ab223052; Abcam), CD63 (dilution 1:100; cat. no. ab216130; Abcam), flotillin-1 (dilution 1:500; cat. no. ab13493; Abcam), Cyr61 (dilution 1:1,500; cat. no. ab228592; Abcam) and tumor susceptibility 101 (TSG101; dilution 1:1,000; cat. no. ab30871; Abcam) at 4°C for 12 h, followed by incubation with an HRP-conjugated secondary antibody (dilution 1:10,000; cat. no. ab205718; Abcam) for 120 min at 25°C. Bound antibodies were detected using BM Chemiluminescence Western Blotting kit (cat. no. 11520709001; MilliporeSigma) and ImageJ v1.8 software (National Institutes of Health).

**Cyr61 analysis.** Exosomes were lysed using RIPA buffer containing protease inhibitors (Beyotime Institute of Biotechnology). Cyr61 levels were then measured using the CYR61 ELISA kit (cat. no. SBJ-H0152; Nanjing SenBeiJia Biological Technology Co., Ltd.) according to the manufacturer's instructions. Calibration and standardization of the assay was performed according to the manufacturer's protocol.

**Cell culture and oxidized low-density lipoprotein (ox-LDL) treatment.** Human VSMCs from the National Infrastructure of Cell Line Resource (cat. no. 4201HUM-CCTCC00632) were cultured in DMEM (Thermo Fisher Scientific, Inc.) containing 10% FBS (Thermo Fisher Scientific, Inc.) and incubated at 37°C with 5% CO₂. To construct the atherosclerosis model *in vitro*, VSMCs were treated with ox-LDL (Shanghai Yeasen Biotechnology Co., Ltd.) at different concentrations (25, 50 and 100 mg/ml) for 24 h at 37°C. In addition, VSMCs were treated with ox-LDL (50 mg/ml) for different times (12, 24 and 48 h) at 37°C.

**Cell transfection.** Small interference RNA (siRNA) and negative control (NC) for Cyr61 were synthesized by Sangon Biotech Co., Ltd. VSMCs (1×10⁶ cells/ml) were cultured in DMEM (Thermo Fisher Scientific, Inc.) containing 10% FBS (Thermo Fisher Scientific, Inc.) and supplemented with 30% FBS. After a 48-h culture at 37°C, VSMCs that failed to migrate to the lower chamber were removed. Next, the lower membrane was fixed with 4% paraformaldehyde for 30 min at 25°C and the migratory cells were stained with 0.1% crystal violet for 20 min at 25°C. Migratory cells from five randomly chosen fields (magnification, x40) from each chamber were photographed using light microscopy and counted using ImageJ v1.8 software (National Institutes of Health).

**Cell Counting Kit-8 (CCK-8) assay.** siCyr61-transfected VSMCs were treated with ox-LDL (50 mg/ml). Subsequently, VSMCs were incubated in binding buffer (1×10⁶ cells/ml), followed by staining with Annexin V-FITC (200 μl) and propidium iodide (PI) solutions (10 μl) at 25°C for 15 min using the Annexin V-FITC/PI Apoptosis Detection kit (cat. no. A211-01; Vazyme Biotech Co., Ltd.) according to the manufacturer's instructions. The apoptotic rate was detected using a flow cytometer (FACSCanto III; BD Biosciences) and FlowJo v10.4 software (BD Biosciences).

**Transwell assay.** siCyr61-transfected VSMCs were treated with ox-LDL (50 mg/ml). Subsequently, VSMCs were resuspended in FBS-free DMEM and were placed on the upper chamber of Transwell plates (Corning, Inc.) with a cell density of 1×10⁵ cell/ml. Subsequently, the bottom chamber was filled with DMEM supplemented with 30% FBS. After a 48-h culture at 37°C, VSMCs that failed to migrate to the lower chamber were removed. Next, the lower membrane was fixed with 4% paraformaldehyde for 30 min at 25°C and the migratory cells were stained with 0.1% crystal violet for 20 min at 25°C. Migratory cells from five randomly chosen fields (magnification, x40) from each chamber were photographed using light microscopy and counted using ImageJ v1.8 software (National Institutes of Health).

**Statistical analysis.** Statistical analyses in the present study were conducted using SPSS 22.0 software (IBM Corp.). χ² test, Fisher's exact test and t-test were performed for comparisons between two groups. Differences among > two groups were evaluated by one-way analysis of variance followed by Tukey's test. The ROC curves were constructed to evaluate the diagnostic accuracy of exosomal Cyr61. A multivariate analysis was applied to identify independent predictors of the existence of ACS. A two-tailed P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Clinicopathological characteristics of the study participants.** The biochemical and clinical parameters of the 160 patients with UAP, 50 patients with AMI and 50 healthy individuals are presented in Table I. No significant difference was observed in the distribution of age, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP) or history of hypertension, diabetes, dyslipidemia or smoking. However, compared with those in healthy subjects, the male sex was significantly more prevalent among patients with ACS. Furthermore, between healthy UAP patients and AMI patients, there were significant differences in ejection fraction (EF), hemoglobin A1c (HbA1c), creatinine (CR), glucose and high-sensitivity C-reactive protein (hs-CRP; all P<0.05; Table I).

**Expression pattern of exosomal Cyr61 in patients with ACS.** Firstly, plasma exosomes were isolated from blood samples collected from healthy individuals, patients with UAP and patients with AMI. Transmission electron microscopy and
nanoparticle tracking analysis revealed that the plasma exosomes displayed a round-shaped morphology with diameters ranging from 60 to 110 nm (Fig. 1A). The size distribution of the exosomes isolated from healthy individuals, UAP, and AMI plasma samples was 85.73±10.13, 89.7±10.81 and 87.56±13.92 nm, respectively (Fig. 1B). Furthermore, the expression of exosome markers CD9, CD63, flotillin and TSG101 were examined by western blotting. Exosomes isolated from healthy individuals, patients with UAP and patients with AMI were tested positive for CD9 expression in addition to CD63, flotillin and TSG101 (Fig. 1C). To assess the expression pattern of Cyr61 derived from the exosomes, ELISA was performed. As shown in Fig. 1D, the level of Cyr61 in exosomes isolated from patients with ACS was significantly higher compared with that in healthy individuals (P<0.001). Subsequently, changes in exosomal Cyr61 levels among the three ACS subtypes were evaluated. Compared with those in healthy individuals, exosome-derived Cyr61 levels in the UAP subgroup (P<0.001; Fig. 1D) or AMI subgroup (P<0.01) were also significantly higher. However, there was no significant difference in exosomal Cyr61 levels between those in the UAP and AMI subgroups (Fig. 1D).

**Association of exosomal Cyr61 levels with clinical characteristics.** Based on the median value of exosomal Cyr61 levels obtained from ELISA experiments, the 210 patients with ACS were equally divided into two groups, the high Cyr61 group (exosomal Cyr61 >1.545 pg/ml) and the low Cyr61 group (exosomal Cyr61 <1.545 pg/ml). Association analysis of exosomal Cyr61 levels with the clinical characteristics of the 210 patients with ACS were then performed. As shown in Table II, high exosomal Cyr61 levels were significantly associated with sex (P=0.016), family history of ACS (P=0.002) and glucose levels (P=0.001). By contrast, there is no significant association between exosomal Cyr61 levels and other parameters, namely age, BMI, SBP, DBP, left ventricular internal diameter (LVID) at diastole, LVID at systole, left atrial, fractional shortening, EF, HbA1c, CR, estimated glomerular
filtration rate, TG, TC, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and hs-CRP (Table II).

Evaluation of exosomal Cyr61 as a diagnostic marker. Given that Cyr61 levels were significantly higher in plasma exosomes of patients with ACS, the diagnostic accuracy of exosomal Cyr61 as a biomarker to discriminate patients with ACS from healthy subjects was evaluated further. As shown in Fig. 2A and Table III, exosomal Cyr61 levels could differentiate between patients with ACS and healthy subjects with high accuracy [area under the curve (AUC), 0.763; 95% confidence interval (CI), 0.705-0.822; P<0.01]. At the cut-off value of 1.435 pg/ml for exosomal Cyr61, the optimal sensitivity and specificity were 55.2 and 92%, respectively. Subsequently, the efficiency of using exosomal Cyr61 as a diagnostic marker for identifying the ACS subgroups was analyzed.

ROC curve analyses (Fig. 2B and Table III) revealed that exosomal Cyr61 could discriminate patients with UAP from healthy individuals with AUC values of 0.790 (95% CI, 0.730-0.851; P<0.001). The optimal cut-off value of exosomal Cyr61 was 1.435 pg/ml (57.5% sensitivity and 92% specificity) to detect UAP. Furthermore, exosomal Cyr61 was also found to be an accurate marker for discriminating patients with AMI from healthy individuals, with AUC values of 0.678 (95% CI, 0.567-0.788; P=0.002). At the cut-off value of 1.485 pg/ml for exosomal Cyr61, the optimal sensitivity and specificity were 48 and 94%, respectively (Fig. 2C and Table III). However, the ability of exosomal Cyr61 in differentiating patients with UAP from patients with AMI was not satisfactory (P=0.136; Fig. 2D and Table III).

Multivariable logistic regression analyses were subsequently performed to identify potential independent contribution of each parameter to the presence of ACS. The results (Table IV) revealed that exosomal Cyr61 (P<0.001) and CR (P=0.001) were independently associated with the presence of ACS. However, EF, HbA1c, glucose and hs-CRP levels were not significantly associated with ACS (Table IV).

Cyr61 regulates proliferation and migration in ox-LDL-stimulated VSMCs. To investigate the role of Cyr61 in atherosclerosis, the expression levels of Cyr61 were measured in VSMCs after stimulation with ox-LDL. As shown in Fig. 3A and B, Cyr61 levels were significantly increased in VSMCs following a 24-h exposure to ox-LDL in a concentration-dependent manner. Ox-LDL treatment also induced a significant increase in Cyr61 expression in a time-dependent manner (Fig. 3C and D). Subsequently, the efficiency of Cyr61 knockdown was confirmed after using siRNAs in VSMCs: siCyr61 transfection significantly decreased the expression level of Cyr61 compared with the NC.
let al: DIAGNOSTIC VALUE OF EXOSOMAL Cyr61 IN ACS

Moreover, the increased expression of Cyr61 induced by ox-LDL was partially inhibited by siCyr61 transfection (P<0.01; Fig. 3F and G). Cell viability analysis revealed that, when compared with that in the control group, exposure to ox-LDL (50 µg/ml) significantly enhanced cell viability (P<0.01), whilst knocking down Cyr6 expression significantly reduced cell viability in the presence of ox-LDL at 48 and 72 h, compared with the ox-LDL group (P<0.01; Fig. 3H). Furthermore, following treatment with 50 µg/ml ox-LDL for 24 h, the levels of cell apoptosis were significantly reduced (P<0.01; Fig. 3I and J). By contrast, Cyr61 knockdown significantly increased the apoptosis rate of VSMCs compared with that in the ox-LDL group (P<0.01; Fig. 3I and J). In addition, a significant increase in the number of migratory cells was observed in response to ox-LDL treatment, then was partially but significantly reversed by Cyr61 knockdown (P<0.01; Fig. 3K and L).

Discussion

ACS remains a major health concern worldwide despite advances in treatment strategies (27). There is a demand for highly sensitive and specific biomarkers for ACS to facilitate ACS diagnosis. In the present study, Cyr61 expression was first profiled in plasma-derived exosomes, which found that the levels of exosomal Cyr61 were increased in patients with UAP and AMI compared with those in healthy individuals. In addition, the levels of exosomal Cyr61 were found to be significantly associated with sex and glucose levels. Subsequently, the results of ROC curve analyses indicated that exosomal Cyr61 could effectively differentiate patients with UAP, AMI and ACS from healthy individuals. Multivariable logistic regression analyzes showed that high exosomal Cyr61 levels was independently associated with the presence of ACS. The role of Cyr61 in vitro was then explored, which found that the elevated cell viability and migration induced by ox-LDL was reversed by Cyr61 knockdown, which also significantly increased the rate of apoptosis in VSMCs compared with cells exposed to ox-LDL alone. These results suggest that increased Cyr61 levels were associated with atherosclerosis, which may provide a rationale for the application of exosomal Cyr61 levels in the clinical diagnosis of ACS.

Previous studies have reported the value of using Cyr61 for the diagnosis and prognosis of ACS (23,24,28). Klingenberg et al (23) reported that the diagnostic accuracy of Cyr61 was superior to that of high sensitivity-troponin T

Table II. Association of exosomal Cyr61 levels with clinical and biochemical parameters.

| Parameters                              | Low Cyr61 group (n=105) | High Cyr61 group (n=105) | t/χ²-value | P-value |
|-----------------------------------------|-------------------------|--------------------------|------------|---------|
| Age, years                              | 66.48±9.95              | 66.9±11.34               | 0.291      | 0.771   |
| Sex, male/female                        | 81/24                   | 65/40                    | 5.753      | 0.016   |
| Body mass index, kg/m²                  | 23.94±3.04              | 23.36±2.32               | 1.557      | 0.121   |
| Systolic blood pressure, mmHg           | 144.21±108.79           | 137.4±22.94              | 0.624      | 0.533   |
| Diastolic blood pressure, mmHg          | 77.37±11.20             | 78.47±12.09              | 0.681      | 0.497   |
| Hypertension, N (%)                     | 74 (70.48)              | 77 (73.33)               | 0.212      | 0.645   |
| Diabetes, N (%)                         | 28 (26.67)              | 26 (24.76)               | 0.1        | 0.752   |
| Dyslipidemia, N (%)                     | 33 (31.43)              | 27 (25.71)               | 0.840      | 0.359   |
| Smoking, N (%)                          | 38 (36.19)              | 28 (26.67)               | 2.210      | 0.137   |
| Family history, N (%)                   | 5 (4.76)                | 19 (18.10)               | 9.220      | 0.002   |
| LVID at diastole, cm                    | 5±0.50                  | 4.86±0.61                | 1.837      | 0.068   |
| LVID at systole, cm                     | 3.14±0.63               | 3.11±0.68                | 0.376      | 0.707   |
| Left atrial, cm                         | 3.96±0.60               | 3.86±0.58                | 1.151      | 0.251   |
| Fractional shortening, %               | 37.25±7.47              | 36.99±7.53               | 0.246      | 0.806   |
| Ejection fraction, %                    | 65.25±11.23             | 65.59±10.83              | 0.225      | 0.822   |
| Hemoglobin A1c, %                       | 6.13±1.30               | 5.97±0.91                | 1.019      | 0.309   |
| Creatinine, µmol/l                     | 86.3±21.92              | 82.1±18.63               | 1.493      | 0.137   |
| Estimated glomerular filtration rate, ml/min | 75.92±16.29          | 76.39±16.51              | 0.208      | 0.835   |
| Glucose, mmol/l                         | 6.48±2.61               | 5.54±1.12                | 3.388      | 0.001   |
| Triglyceride, mmol/l                    | 1.58±0.89               | 1.62±1.04                | 0.300      | 0.765   |
| Total cholesterol, mmol/l               | 4.27±1.17               | 4.27±1.14                | 0.009      | 0.993   |
| High-density lipoprotein cholesterol, mmol/l | 1.23±0.31             | 1.17±0.26                | 1.493      | 0.137   |
| Low-density lipoprotein cholesterol, mmol/l | 2.32±0.83              | 2.4±0.82                 | 0.716      | 0.475   |
| High-sensitivity C-reactive protein, mg/l | 12.18±22.24            | 9.64±17.5               | 0.921      | 0.358   |

According to the median of exosomal Cyr61 levels, ACS patients were divided into two groups: low Cyr61 group (exosomal Cyr61 <1.545 pg/ml; n=105) and high Cyr61 group (exosomal Cyr61 >1.545 pg/ml; n=105). Cyr61, cysteine-rich protein 61; LVID, left ventricular internal diameter.
for detecting coronary thrombi in a subset of 1641 patients with available data, which was subsequently confirmed by angiography. However, these authors found that the sensitivity (55%) and specificity (70%) of Cyr61 for ACS diagnosis was moderate (23). Exosomes containing nucleic acids, proteins and lipids are secreted by membrane-enclosed vesicles (extracellular vesicles) and can be released into a variety of bodily fluids, including plasma, saliva and urine (29,30).

Accumulating evidence supports the notion that exosomal cargos can be used as a diagnostic biomarker of ACS (16,31). For instance, Ling et al (3) found that serum exosomal miRNA-21, miRNA-126 and PTEN are novel biomarkers for the diagnosis of ACS. Therefore, for the present study the potential of exosomal Cyr61 for ACS diagnosis was explored. It was found that exosomal Cyr61 levels were higher in patients with UAP and AMI compared with those in healthy

### Table III. Data obtained from the receiver operating characteristic curve corresponding to results shown in Fig. 2, including AUC, 95% CI, sensitivity, specificity and Youden index.

| Indices        | AUC     | 95% CI (Down-up) | P-value | Sensitivity (%) | Specificity (%) | Youden index | Cut-off value |
|----------------|---------|------------------|---------|-----------------|-----------------|--------------|--------------|
| ACS vs. healthy | 0.763   | 0.705-0.822      | <0.001  | 55.2            | 92              | 0.472        | 1.435        |
| UAP vs. Healthy | 0.790   | 0.730-0.851      | <0.001  | 57.5            | 92              | 0.495        | 1.435        |
| AMI vs. Healthy | 0.678   | 0.567-0.788      | 0.002   | 48              | 94              | 0.420        | 1.485        |
| UAP vs. AMI    | 0.430   | 0.333-0.527      | 0.136   | 90              | 93.7            | 0.038        | 3.155        |

ACS, acute coronary syndrome; UAP, unstable angina pectoris; AIM, acute myocardial infarction; AUC, area under the curve; CI, confidence interval. The cut-off value was the level with maximum Youden index.

Figure 2. ROC curves of exosomal Cyr61 levels. ROC curves used to assess the diagnostic accuracy of exosomal Cyr61 levels in patients with (A) AUC, (B) UAP and (C) AMI. The diagnostic accuracy to discriminate (D) patients with UAP from patients with AMI was also analyzed. ROC, receiver operating characteristic; Cyr61, cysteine-rich protein 61; UAP, unstable angina pectoris; ACS, acute coronary syndrome; AMI, acute myocardial infarction.
The corresponding univariate analysis is shown in Table I. Cyr61, cysteine-rich protein 61.

Table IV. Multivariate analysis of the association between exosomal Cyr61 levels and acute coronary syndrome.

| Variables                      | β value | Standard error | Wald  | P-value | Exp (β) | Lower | Upper |
|--------------------------------|---------|----------------|-------|---------|---------|-------|-------|
| Ejection fraction              | -0.009  | 0.020          | 0.204 | 0.652   | 0.991   | 0.952 | 1.031 |
| Hemoglobin A1c                 | 0.249   | 0.238          | 1.100 | 0.294   | 1.283   | 0.805 | 2.045 |
| Creatinine                     | 0.056   | 0.016          | 11.815| 0.001   | 1.058   | 1.024 | 1.092 |
| Glucose                        | 0.096   | 0.145          | 0.443 | 0.506   | 1.101   | 0.829 | 1.462 |
| High-sensitivity C-reactive protein | 0.018  | 0.019          | 0.852 | 0.356   | 1.018   | 0.980 | 1.057 |
| Exosomal Cyr61                 | 1.980   | 0.384          | 26.619| <0.001  | 7.242   | 3.414 | 15.365 |

The ability of exosomal Cyr61 in differentiating patients with UAP from patients with AMI was not satisfactory. Therefore, additional indicators in combination with exosomal Cyr61 may be needed to make this distinction.

Exosomes are derived from blood vessels and other tissues, which can be used to reflect molecular information about ACS (12-15). Some cell types, such as tumor cells and dendritic cells, can secrete larger quantities of exosomes compared with normal cells (35,36). It was reported that tumor cell-derived normal exosomes have a relatively stable structure, which can protect its cargos from destruction (37). These reported characteristics suggest that the detection of exosomal Cyr61 can be more specific than serum Cyr61. At present, exosomes can be rapidly extracted, which can be exploited to monitor changes in the expression of molecular markers during the process of ACS pathogenesis (38). The advantage of exosomes and findings from the present study suggest that exosomal Cyr61 is an able biomarker for ACS diagnosis.

Atherosclerosis is one of the most frequently observed pathological process underlying cardiovascular diseases (39). It is a multistep process that involves the production of proinflammatory cytokines, accumulation of macrophages and dysfunction of endothelial and VSMCs (40-42). Vascular remodeling is closely associated with atherosclerosis progression, where the main cause is aberrant VSMC proliferation and migration, which ultimately result in neointimal hyperplasia (42-44). Therefore, understanding the role of Cyr61 in vascular remodeling will contribute to improving the clinical diagnostic strategy of ACS.

In the present study, an in vitro model of atherosclerosis was established using ox-LDL-stimulated VSMCs. A significant increase in Cyr61 levels was found in VSMCs after ox-LDL treatment, suggesting that Cyr61 is involved in vascular remodeling. Subsequently, it was found that Cyr61 knockdown reversed the increases in cell viability whilst also reversing the reduction in VSMC apoptosis induced by ox-LDL. These findings concur with those from a previous study, where Cyr61 upregulated the migration and proliferation of mouse aortic smooth muscle cells (45). These data suggest that Cyr61 is involved in vascular remodeling in vitro, which also supports the reported association between Cyr61
levels and ACS. Furthermore, the present study provided a theoretical basis for the clinical application of exosomal Cyr61 for ACS diagnosis.

In conclusion, the present study reported an increase in the expression of exosomal Cyr61, which associated with sex, family history and glucose levels. Exosomal Cyr61 was found...
to be a promising biomarker for discriminating patients with UAP and AMI, providing initial insights into the role of using exosomal Cyr61 levels for the diagnosis of ACS. Functionally, Cyr61 participates in vascular remodeling in vitro. These results suggest that exosomal Cyr61 can be translated into a blood-based biomarker for clinical application.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

WL conceived and designed the study. WL, YL, WZ, CL, WF, and XG provided study materials or patients. WL, WF, QM collected and assembled data. WL, YL, WZ, CL and XG analyzed and interpreted data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the Institutional Ethics Committee of the Second Hospital of Hebei Medical University (Shijiazhuang, China). Written informed consent was obtained from every participant in the present study.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A and Chakraborty S: A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol 234: 16812-16823, 2019.

2. Khera AV and Kathiresan S: Genetics of coronary artery disease: Discovery, biology and clinical translation. Nat Rev Genet 18: 16812-16823, 2019.

3. Ling H, Guo Z, Shi Y, Zhang L and Song C: Serum exosomal MicroRNA-21, MicroRNA-126, and PTEN are novel biomarkers for diagnosis of acute coronary syndrome. Front Physiol 11: 654, 2020.

4. Kandaswamy E and Zuo L: Recent advances in treatment of coronary artery disease: Role of science and technology. Int J Mol Sci 19: 424, 2018.

5. Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, Domanski MJ, Forkah ME, Flather M, Fuster V, et al: Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet 391: 939-948, 2018.

6. Linde JJ, Kelbæk H, Hansen TF, Sigvardsen PE, Torp-Pedersen C, Bech J, Heitmann M, Nielsen OW, Høftsten D, Kühl JT, et al: Coronary CT angiography in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol 75: 453-463, 2020.

7. Garg P, Morris P, Fazlani AL, Vijayan S, Dancso B, Dastidar AG, Plein S, Mueller C and Hafn P: Cardiac biomarkers of acute coronary syndrome: From history to high-sensitivity cardiac troponin. Intern Emerg Med 12: 147-155, 2017.

8. Omland T: Can circulating B-type natriuretic peptide concentrations guide treatment of obstructive left main coronary artery disease? Circulation 138: 479-482, 2018.

9. Zhu M, Lin J, Wang C, Yang M, Lv H, Yang M, Xu B, Chen X and Jiang J: The relationship among angiotensinogen genes polymorphisms and hs-CRP and coronary artery disease. J Clin Lab Anal 33: e22891, 2019.

10. Miki K, Kitamura M, Hatta K, Kamide K, Gondo Y, Yamashita M, Takedachi M, Nozaki T, Fujihara C, Kashiwagi Y, et al: Periodontal inflamed surface area is associated with hs-CRP in septuagenarian Japanese adults in cross-sectional findings from the SONIC study. Sci Rep 11: 14436, 2021.

11. Yeh JC, Wu CC, Choy CS, Chang SW, Liu JC, Chen KS, Tung TH, Lin WN, Hsieh CY, Ho CT, et al: Non-hepatic alkaline phosphatase, hs-CRP and progression of vertebral fracture in patients with rheumatoid arthritis: A population-based longitudinal study. J Clin Med 7: 439, 2018.

12. Kalluri R and LeBlu VS: The biology, function, and biomedical applications of exosomes. Science 367: eaau9777, 2020.

13. Wang Y, Xie Y, Zhang A, Wang M, Fang Z and Zhang J: Exosomes: An emerging factor in atherosclerosis. Biomed Pharmacother 115: 108951, 2019.

14. Chan BD, Wong WY, Lee MM, Cho WC, Yee BK, Kwan YW and Tai WC: Exosomes in inflammation and inflammatory disease. Proteomics 19: e1800149, 2019.

15. Gao XF, Wang ZM, Wang F, Gu Y, Zhang JJ and Chen SL: Exosomes in coronary artery disease. Int J Biol Sci 15: 2461-2470, 2019.

16. Li X, He X, Wang J, Wang D, Cong P, Zhu A and Chen W: The regulation of exosome-derived miRNA on heterogeneity of macrophages in atherosclerotic plaques. Front Immunol 11: 2175, 2020.

17. Yao Y, Sun W, Sun Q, Jing B, Liu S, Liu X, Shen G, Chen R and Wang H: Platelet-derived exosomal MicroRNA-25-3p inhibits coronary vascular endothelial cell inflammation through adaml0 via the NF-kB signaling pathway in ApoE(-/-) mice. Front Immunol 10: 2205, 2019.

18. Li J, Tan M, Xiang Q, Zhou Z and Yan H: Thrombin-activated platelet-derived exosomes regulate endothelial cell expression of ICAM-1 via microRNA-223 during the thrombosis-inflammation response. Throm Res 154: 96-105, 2017.

19. Ling H, Guo Z, Du S, Liao Y, Li Y, Ding C and Song C: Serum exosomal miR-122-5p is a new biomarker for both acute coronary syndrome and underlying coronary artery stenosis. Biomarkers 25: 539-547, 2020.

20. Li LJ, Gu YJ, Wang LQ, Wan W, Wang HW, Yang XN, Ma LL, Yang LH and Meng ZH: Serum exosomal microRNA-146a as a novel diagnostic biomarker for acute coronary syndrome. J Thorac Dis 13: 3105-3114, 2021.

21. Yang Y, Qi Q, Wang Y, Shi Y, Yang W, Cen Y, Zhu E, Li X, Chen D and Wang B: Cysteine-rich protein 61 regulates adipocyte differentiation from mesenchymal stem cells through mammalian target of rapamycin complex 1 and canonical Wnt signaling. FASEB J 32: 3096-3107, 2018.

22. Song Y, Lin Q, Cai Z, Hao T, Zhang Y and Zhu X: Cysteine-rich protein 61 regulates the chemosensitivity of chronic myeloid leukemia to imatinib mesylate through the nuclear factor kappa B/Bcl-2 pathway. Cancer Sci 110: 2421-2430, 2019.

23. Klingenberg R, Aghlmandi S, Liebetrau C, Räber L, Gencer B, Nanchen D, Carballo D, Akhmedov A, Montecucco F, Zoller S, et al: Cysteine-rich angiogenic inducer 61 (Cyr61): A novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes. Eur Heart J 38: 3493-3502, 2017.

24. Liu C, Cao Y, He X, Zhang C, Liu J, Zhang L, Wu D, Zhuang X, Xue R, Huang H, et al: Association of Cyr61-cysteine-rich protein 61 and short-term mortality in patients with acute heart failure and coronary heart disease. Biomark Med 13: 1589-1597, 2019.

25. Liang Q, Qian X, Li J, Li Y, Li Y and Luo Y: Evaluation of serum cysteine-rich protein 61 levels in patients with coronary artery disease. Biomark Med 12: 329-339, 2018.
26. Rajpurohit N, Ayaz SZ, Yee J, Khan MA and Stys A: Review of acute coronary syndromes: Diagnosis and management of unstable angina and non ST-elevation myocardial infarction. S D Med 68: 71-73, 2015.

27. Ferrari R and Fox K: Heart rate reduction in coronary artery disease and heart failure. Nat Rev Cardiol 13: 493-501, 2016.

28. Zhao J, Zhang C, Liu J, Zhang L, Cao Y, Wu D, Yao F, Xue R, Huang H, Jiang J, et al: Prognostic significance of serum cysteine-rich protein 61 in patients with acute heart failure. Cell Physiol Biochem 48: 1177-1187, 2018.

29. Koritzinsky EH, Street JM, Star RA and Yuen PS: Quantification of exosomes. J Cell Physiol 232: 1587-1590, 2017.

30. Kumar D, Narang R, Sreenivas V, Rastogi V, Bhatia J, Saluja D and Srivastava K: Circulatory miR-133b and miR-21 as novel biomarkers in early prediction and diagnosis of coronary artery disease. Genes (Basel) 11: 164, 2020.

31. Choi C, Jeong W, Ghang B, Park Y, Hyun C, Cho M and Kim J: Cyr61 synthesis is induced by interleukin-6 and promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther 22: 275, 2020.

32. Seino Y, Ikeda U, Ikeda M, Yamamoto K, Misawa Y, Hasegawa T, Kano S and Shimada K: Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 6: 87-91, 1994.

33. Feng B, Xu G, Sun K, Duan K, Shi B and Zhang N: Association of serum Cyr61 levels with peripheral arterial disease in subjects with type 2 diabetes. Cardiovasc Diabetol 19: 194, 2020.

34. Zhao L, Yu J, Wang J, Li H, Che J and Cao B: Isolation and identification of miRNAs in exosomes derived from serum of colon cancer patients. J Cancer 8: 1145-1152, 2017.

35. Li X, Li X, Lin J, Sun X and Ding Q: Exosomes derived from low-intensity pulsed ultrasound-treated dendritic cells suppress tumor necrosis factor-induced endothelial inflammation. J Ultrasound Med 38: 2081-2091, 2019.

36. Ren J, He W, Zheng L and Duan H: From structures to functions: Insights into exosomes as promising drug delivery vehicles. Biomater Sci 4: 910-921, 2016.

37. De Toro J, Herschlik L, Waldner C and Mongini C: Emerging roles of exosomes in normal and pathological conditions: New insights for diagnosis and therapeutic applications. Front Immunol 6: 203, 2015.

38. Geovanini GR and Libby P: Atherosclerosis and inflammation: Overview and updates. Clin Sci (Lond) 132: 1243-1252, 2018.

39. Grootaert MOJ, Moulis M, Roth L, Martinet W, Vindis C, Bennett MR and De Meyer GRY: Vascular smooth muscle cell death, autophagy and senescence in atherosclerosis. Cardiovasc Res 114: 622-634, 2018.

40. Liu D, Zeng X, Li X, Mehta JL and Wang X: Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases. Basic Res Cardiol 113: 5, 2017.

41. Basatemur GL, Jørgensen HF, Clarke MCH, Bennett MR and Mallat Z: Vascular smooth muscle cells in atherosclerosis. Nat Rev Cardiol 16: 727-744, 2019.

42. Frisanti Sa, Philippova M, Erne P and Resink TJ: Smooth muscle cell-driven vascular diseases and molecular mechanisms of VSMC plasticity. Cell Signal 52: 48-64, 2018.

43. Serino A and Salazar G: Protective role of polyphenols against vascular inflammation, aging and cardiovascular disease. Nutrients 11: 53, 2018.

44. Imhof BA, Jemelin S, Ballet R, Vesin C, Schapira M, Karaca M and Emre Y: CCN1/CYR61-mediated meticulous patrolling by Ly6Clow monocytes fuels vascular inflammation. Proc Natl Acad Sci USA 113: E4847-E4856, 2016.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.